Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

Clinical Study on Modified Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.

The purpose of this study was to assess the potential of boron neutron capture therapy (BNCT), with a 6-h infusion of the boron carrier l-boronophenylalanine as a fructose preparation (BPA-f), as first-line radiotherapy for newly diagnosed glioblastoma multiforme (GBM). Patient survival data from a Phase II study using BNCT were compared with retrospective data from the two arms of a Phase III ...

Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: comparison of clinical results obtained with BNCT and conventional treatment.

The purpose of this study was to evaluate the clinical outcome of boron neutron capture therapy (BNCT) and conventional treatment in patients with newly diagnosed glioblastoma. Since 1998 we treated 23 newly-diagosed GBM patients with BNCT without any additional chemotherapy. Their median survival time was 19.5 months; the 2-, 3-, and 5-year survival rates were 31.8%, 22.7%, and 9.1%, respectiv...

Boron Neutron Capture Therapy

A project aimed at the development of an accelerator facility devoted to Boron Neutron Capture Therapy (BNCT) is ongoing at the National Atomic Energy Commission of Argentina [1]. In a first stage of development, the accelerator will be capable of delivering proton or deuteron beams of 30 mA at about 1.4 MeV which is suitable for neutron production through the 9Be(d,n) reaction. In this context...

Boron neutron capture therapy for cancer.

*1102 Expression of Neural Cell Adhesion Molecule-related Sialoglycoprotein in Small Cell Lung Cancer and Neuroblastoma Cell Lines 1169 and CHP-212. C. E. C. Kitty Moolenaar. Egbert J. Muller, Dick J. Schol, Carl G. Figdor, Elizabeth Bock. Dieter Bitter-Suermann. and Rob J. A. M. Michalides. * 1107 Prolongation of Serum Half-Life of Interleukin 2 and Augmenta tion of Lymphokine-activated killer...